Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million Read more about Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015 Read more about Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA Read more about Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
Bone Therapeutics announces its financial calendar for 2015 Read more about Bone Therapeutics announces its financial calendar for 2015
Information on the total number of voting rights and shares Read more about Information on the total number of voting rights and shares
Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial Read more about Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial
Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial Read more about Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
Bone Therapeutics Establishes US Subsidiary Read more about Bone Therapeutics Establishes US Subsidiary
Bone Therapeutics officially opens its new headquarters in Gosselies Read more about Bone Therapeutics officially opens its new headquarters in Gosselies
Bone Therapeutics Reports 2014 Financial and Operational Results Read more about Bone Therapeutics Reports 2014 Financial and Operational Results